Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; Department of Chemistry, Seoul National University, Seoul, Republic of Korea; Center for Genome Engineering, Institute for Basic Science, Daejeon, Republic of Korea.
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea.
Pharmacol Ther. 2020 May;209:107501. doi: 10.1016/j.pharmthera.2020.107501. Epub 2020 Feb 13.
Genome engineering technologies right from viral vector-mediated to protein-based editing- which include zinc finger nucleases, TALENs, and CRISPR/Cas systems-have been improved significantly. These technologies have facilitated drug discovery and have resulted in the development of potential curative therapies for many intractable diseases. They can efficiently correct genetic errors; however, these technologies have limitations, such as off-target effects and possible safety issues, which need to be considered when employing these techniques in humans. Significant efforts have been made to overcome these limitations and to accelerate the clinical implementation of these technologies. In this review, we focus on the recent technological advancements in genome engineering and their applications in stem cells to enable efficient discovery of drugs and treatment of intractable diseases.
基因组编辑技术从病毒载体介导到基于蛋白质的编辑——包括锌指核酸酶、TALEN 和 CRISPR/Cas 系统——已经得到了显著的改进。这些技术促进了药物的发现,并为许多难治性疾病开发了潜在的治疗方法。它们可以有效地纠正遗传错误;然而,这些技术也有局限性,如脱靶效应和可能的安全问题,在将这些技术应用于人类时需要考虑这些问题。人们已经做出了巨大的努力来克服这些局限性,并加速这些技术的临床应用。在这篇综述中,我们重点介绍了基因组工程的最新技术进展及其在干细胞中的应用,以实现药物的高效发现和难治性疾病的治疗。